R Michael Carruthers
CIK 1644467 · Chief Financial Officer · last filed 2026-06-08
R Michael Carruthers is a Chief Financial Officer who has filed 33 SEC Form 4 insider transactions across 5 companies since 2015. The most recent filing, for OKUR, was dated Jun 8, 2026. Across all open-market trades the lifetime net is −$5.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$3.77M
5
33
-$5.04M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OKUR | Director | 4,939 | $4.14 | $20.4K | $0 | 3 | 2026-06-08 |
| EWTX | Chief Financial Officer | 86,162 | $43.52 | $3.75M | -$5.09M | 14 | 2025-08-14 |
| Elevation Oncology, Inc. (ELEV) Delisted | Director | — | $0.36 | — | $0 | 5 | 2025-07-24 |
| Fresh Tracks Therapeutics, Inc. (BBI) Delisted | Chief Financial Officer | — | $2.35 | — | $0 | 1 | 2020-03-18 |
| ALPINE IMMUNE SCIENCES, INC. (NVLS) Delisted | Interim President / CFO | 6,000 | — | — | $50.3K | 4 | 2017-01-23 |
Recent Filings
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-08 | OKUR | Grant (A) | — | $0 | EDGAR |
| 2026-01-20 | EWTX | Notice (144) | −183,867 | -$5.17M | EDGAR |
| 2026-01-15 | EWTX | Notice (144) | −180,872 | -$4.80M | EDGAR |
| 2025-12-29 | EWTX | Notice (144) | −116,665 | -$3.04M | EDGAR |
| 2025-11-17 | EWTX | Notice (144) | −70,000 | -$1.57M | EDGAR |
| 2025-08-14 | EWTX | Mixed | +4,353 | -$19.1K | EDGAR |
| 2025-07-24 | Elevation Oncology, Inc. (ELEV) Delisted | Disp (D) | — | $0 | EDGAR |
| 2025-06-09 | Elevation Oncology, Inc. (ELEV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-05-30 | OKUR | Grant (A) | — | $0 | EDGAR |
| 2025-05-07 | EWTX | Mixed | +3,895 | -$21.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.